Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer Read more about Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer
Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC Read more about Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC
Zai Lab Announces Closing of Hong Kong Secondary Listing Read more about Zai Lab Announces Closing of Hong Kong Secondary Listing
Zai Lab Announces Pricing of Hong Kong Secondary Listing Read more about Zai Lab Announces Pricing of Hong Kong Secondary Listing
Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian c Read more about Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian c
Zai Lab Launches Hong Kong Secondary Listing Read more about Zai Lab Launches Hong Kong Secondary Listing
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China Read more about Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020 Read more about Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020
Zai Lab Announces Upcoming Participation in September Conferences Read more about Zai Lab Announces Upcoming Participation in September Conferences
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer Read more about Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer